22818-59-3Relevant academic research and scientific papers
HETEROCYCLIC AMIDE COMPOUND
-
Paragraph 0231, (2021/10/02)
PROBLEM TO BE SOLVED: To provide a heterocyclic amide compound useful as an active ingredient of a herbicide. SOLUTION: The present disclosure provides a heterocyclic amide compound represented by the following formula or a salt thereof. Q-N(R3)-C(=X)-W (Q: a substituted/unsubstituted 1,3,4-oxadiazole, 1,2,5-oxadiazole or the like. W: a substituted/unsubstituted [1,2,4]triazolo[4,3-a]pyridine or the like. X: O, S. R3: H, C1-C6 alkyl or the like). SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT
HETEROCYCLIC AMIDE COMPOUND
-
Paragraph 0247, (2020/10/31)
PROBLEM TO BE SOLVED: To provide a herbicide that reliably has an effect on various weeds at a reduced dosage, has reduced trouble such as soil pollution and influence on succeeding crops, and is highly safe. SOLUTION: The present invention provides a heterocyclic amide compound represented by the following formula and a herbicide containing the same. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT
HETEROCYCLIC AMIDO COMPOUND
-
Paragraph 0219, (2018/06/28)
PROBLEM TO BE SOLVED: To provide a novel pesticide, especially a herbicide. SOLUTION: There are provided a heterocycle amide compound such as 3-isopropyl-N-(5-methyl-1, 3, 4-oxadiazole-2-yl)-5-(trifluoromethyl)-[1, 2, 4]triazolo [4,3-a] pyridine-8-carboxamide (compound No.1-004), 3-isopropyl-N-(5-methyl-1, 3, 4-oxadiazole-2-yl)-5-(methylthio)-[1,2,4] triazolo [4,3-a] pyridine-8-carboxamide (compound No.1-009), and a herbicide containing them. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT
Angiotensinogen analogs
-
, (2008/06/13)
The invention relates to renin inhibiting compounds of the formula STR1 wherein A is hydrogen; loweralkyl; arylalkyl; OR10 or SR10 wherein R10 is hydrogen, loweralkyl or aminoalkyl; NR11 R12 wherein R11 and R12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; STR2 wherein B is NH, alkylamino, S, O, CH2 or CHOH and R13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH2 or NR2 with the proviso that when W is CHOH then U is CH2 ; R1 is loweralkyl, cycloaklylmethyl, benzyl, α,α-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R1 is phenoxy, thiophenoxy or anilino, B is CH2 or CHOH or A is hydrogen, R3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R5 is loweralkyl, cycloalkylmethyl or benzyl; R2 and R4 are independently selected from hydrogen and loweralkyl; R6 is CHOH or CO; R7 is CH2, CF2 or CF with the proviso that when R6 is CO, R7 is CF2 ; R8 is CH2, CHR14 wherein R14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R7 and R8 taken together can be STR3 with the proviso that when R7 is CF2, R8 is CH2 ; E is O, S, SO, SO2, NR15 wherein R15 is hydrogen or loweralkyl or NR16 CO wherein R16 is hydrogen or loweralkyl; R9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R9 taken together can be N3, with the proviso that when E is NH, R9 is an N-protecting group; and pharmaceutically acceptable salts thereof.
